Ab­b­Vie jumps in­to the fren­zied race for a BC­MA/CD3 bis­pe­cif­ic tar­get­ing mul­ti­ple myelo­ma. Teneo­bio who?

Every­body wants a BC­MA bis­pe­cif­ic. And Ab­b­Vie just front­ed $90 mil­lion to get one from a lit­tle-known Sil­i­con Val­ley biotech called Teneo­bio.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.